Wisdrug Innovation Pharmacy Research

Wisdrug is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages an integrated drug discovery platform that combines computational chemistry and artificial intelligence to target metabolic and inflammatory diseases, including gout and non-alcoholic steatohepatitis (NASH). Its lead candidate, WD-1603, is a potent URAT1 inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, the company is advancing WD-481, a thyroid hormone receptor beta agonist aimed at treating metabolic dysfunction-associated steatohepatitis. Wisdrug aims to address significant unmet medical needs through efficient molecular design and optimized pharmacological profiles.